Target intelligence / Profile preview

TP53-responsive DNA element (p53RE) (p53RE)

Target
p53RE
Molecular classification
Other, DNA regulatory element
01

Overview

TP53-responsive DNA elements (p53REs) are specific nucleotide sequences located within the promoters or enhancers of genes that are transcriptionally regulated by the p53 tumor suppressor protein (Riley et al., 2008, Nature Reviews Molecular Cell Biology). These elements typically consist of two decameric half-sites with the consensus sequence RRRCWWGYYY, which allow the p53 tetramer to bind and initiate the expression of genes involved in cell cycle control, DNA repair, and programmed cell death (Khoo et al., 2014, Cell Death & Differentiation). As the primary site of p53-mediated transcriptional activation, these DNA elements are essential for the guardian of the genome function, preventing the proliferation of cells with damaged DNA (el-Deiry, 1998, Radiation Oncology Investigations). In many cancers, mutations in the TP53 gene result in a protein that can no longer recognize or bind to these specific DNA sequences, leading to the loss of tumor suppression. While the DNA elements themselves are not traditional pharmacological targets like enzymes or receptors, they are the functional focal point for therapies designed to restore p53 activity. Drugs such as Eprenetapopt (APR-246) aim to refold mutant p53 to restore its affinity for these elements, while MDM2 inhibitors like Nutlins increase the concentration of wild-type p53 available to bind these sites (Bykov et al., 2018, Nature Reviews Cancer). Consequently, the occupancy and activation of these DNA elements serve as a critical indicator of the efficacy of p53-targeted cancer therapies.

Other names
p53 response elementp53 binding sitep53-binding DNA motifp53RETP53 binding motif
02

Mechanism of action

Restoration or stabilization of p53 protein binding to DNA response elements to reactivate tumor suppressor gene transcription.

03

Biological functions

Cell cycleApoptosisCell deathOther
04

Disease associations

Cancer
05

Safety considerations

Hematological toxicity (e.g., thrombocytopenia)Gastrointestinal toxicityPotential for selecting p53-deficient resistant clonesOff-target effects in non-cancerous tissues
06

Interacting drugs

Eprenetapopt (APR-246)

5 more in the full profile.

07

Biomarkers

TP53 mutation statusCDKN1A (p21) expressionBBC3 (PUMA) expressionMDM2 expression

Beyond the preview

Go deeper on TP53-responsive DNA element (p53RE) (p53RE).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on TP53-responsive DNA element (p53RE) (p53RE).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call